JHL Forms $257 Million Partnership with Sanofi for Rituximab Biosimilar

JHL Biotech, a Taiwan-China biologics company, signed a $257 million partnership agreement that gives Sanofi  rights to market a JHL clinical-stage rituximab biosimilar, initially for China. Sanofi also invested $80 million in JHL stock. JHL will develop, register and manufacture the biosimilar, while Sanofi will be in charge of commercialization. Rituximab is used to treat autoimmune disorders, cancer and transplant rejection. JHL received approval to start a European Phase I trial of the rituximab biosimilar in February 2016. More details.... Stock Symbols: (TWO: 6540) (NYSE: SNY) Share this with colleagues: // //